Citi Pharma Ltd (CPHL): Retail & Global Initiatives to Generate Explosive growth - By Sherman Research
Feb 10 2025
Sherman Securities
- We initiate coverage on Citi Pharma (CPHL), Pakistan’s leading producer of Active Pharmaceutical Ingredients (APIs), with a ‘Buy’ recommendation. CPHL is offering potential upside of 136% to our SOTP based target of Rs217. We believe that company’s new initiatives like 1) venturing into high margin retail segment and 2) expanding in global markets will help in achieving explosive 3-year (FY25-27) earnings CAGR of 75% which will unlock valuation.
- CPHL is a major API supplier of antibiotics and analgesics market (combined API market size of these products is Rs100bn) to big players like HALEON, SAMI, GLAXO and BARRETT HODGSON. The company is now directly venturing into retail market of same APIs which has a bigger market size of Rs235bn. This will substantially increase company’s revenue and gross margins. Generally, API constitute 35% of the cost and yields gross margins of 13%, whereas, finished product of similar API in retail market sells at a higher price - yielding average gross margin of 45%.
- Over the last few years, CPHL managed to gain reputable presence in public hospitals as a major formulation supplier (finished pharma products without major branding) and is now launching the same products in retail market. Given pricing edge as a leading API manufacturer, the company is offering products at a discounted price enhancing its ability to capture market share in retail market.
Current:
Open:
Volume:
Change: ()
High:
Low:
52 Week High:
Vol Avg(12 m):
Free Float:
52 Week Low:
Market Cap:
Total Share:
Relative Strength Index (RSI)
RSI:
MACD Signals
MACD DAILY:
MACD WEEKLY:
Simple Moving Avg (SMA)
SMA(10):
SMA(30):
SMA(60):
SMA(200):
Performance
One Month:
Three Months:
Six Months:
Twelve Months:
Support & Resistance
Support 1:
Resistance 1:
Support 2:
Resistance 2:
High & Lows
Period
High
Low